Sanofi ( (SNY) ) has issued an announcement.
In March 2025, Sanofi announced that its regulatory submission for tolebrutinib, a brain-penetrant BTK inhibitor for treating non-relapsing secondary progressive multiple sclerosis (nrSPMS), was accepted for priority review by the US FDA. Tolebrutinib, which targets smoldering neuroinflammation, has the potential to be the first therapy to address this key driver of disability in MS, marking a potential paradigm shift in treatment. Additionally, Sanofi’s chlamydia vaccine candidate was granted fast track designation by the US FDA, highlighting the company’s ongoing efforts to innovate in the healthcare sector.
More about Sanofi
Sanofi is a global healthcare company focused on transforming medicine to improve lives. It provides life-changing treatments and vaccines to millions worldwide, emphasizing sustainability and social responsibility. Sanofi is listed on EURONEXT and NASDAQ.
YTD Price Performance: 15.07%
Average Trading Volume: 2,570,041
Technical Sentiment Signal: Strong Sell
Current Market Cap: $137.2B
Find detailed analytics on SNY stock on TipRanks’ Stock Analysis page.